Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
NewsA large Rutgers-led study has linked popular GLP-1 medications — including Ozempic, Wegovy, Mounjaro, and Zepbound — to a small but notable increased risk of ischemic optic neuropathy, a rare condition that can cause sudden, potentially permanent vision loss. The absolute risk is low, but researchers say awareness is critical given how widely these drugs are now prescribed.
A large study published in Annals of Internal Medicine has found that GLP-1 receptor agonists — the blockbuster class of drugs behind Ozempic, Wegovy, Mounjaro, and Zepbound — may slightly raise the risk of ischemic optic neuropathy (ION), a rare condition where reduced blood flow to the optic nerve can trigger sudden, potentially permanent vision loss. Researchers at Rutgers University analyzed data from US adults aged 18–65 with Type 2 diabetes who had recently started these medications.
While the overall risk remains low, the findings are clinically meaningful given the explosive growth in GLP-1 prescriptions. Men and adults aged 50–65 appeared most vulnerable. Researchers stress the association doesn't confirm causation — underlying health differences may play a role — but urge prompt ophthalmologic evaluation if patients notice sudden blurriness, dimming, or blind spots.
By the Numbers
Why it matters: With millions now on GLP-1 medications — many without diabetes — even a rare side effect carries significant public health weight. Clinicians should factor this risk into patient counseling, especially for older male patients.